<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35075293</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>104</StartPage><EndPage>116</EndPage><MedlinePgn>104-116</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-021-01615-z</ELocationID><Abstract><AbstractText>Fused in sarcoma (FUS) is an RNA-binding protein that is genetically and pathologically associated with rare and aggressive forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). To explore the mechanisms by which mutant FUS causes neurodegeneration in ALS-FTD, we generated a series of FUS knock-in mouse lines that express the equivalent of ALS-associated mutant FUSP525L and FUS&#x394;EX14 protein. In FUS mutant mice, we show progressive, age-dependent motor neuron loss as a consequence of a dose-dependent gain of toxic function, associated with the insolubility of FUS and related RNA-binding proteins. In this disease-relevant mouse model of ALS-FUS, we show that ION363, a non-allele-specific FUS antisense oligonucleotide, efficiently silences Fus and reduces postnatal levels of FUS protein in the brain and spinal cord, delaying motor neuron degeneration. In a patient with ALS with a FUSP525L mutation, we provide preliminary evidence that repeated intrathecal infusions of ION363 lower wild-type and mutant FUS levels in the central nervous system, resulting in a marked reduction in the burden of FUS aggregates that are a pathological hallmark of disease. In mouse genetic and human clinical studies, we provide evidence in support of FUS silencing as a therapeutic strategy in FUS-dependent ALS and FTD.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Korobeynikov</LastName><ForeName>Vladislav A</ForeName><Initials>VA</Initials><Identifier Source="ORCID">0000-0002-9127-292X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lyashchenko</LastName><ForeName>Alexander K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0003-0629-0494</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Blanco-Redondo</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0246-2893</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rudolf-Sch&#xf6;nheimer Institute for Biochemistry, Leipzig University, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafar-Nejad</LastName><ForeName>Paymaan</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5176-739X</Identifier><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shneider</LastName><ForeName>Neil A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0002-3223-7366</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, New York, NY, USA. ns327@columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Eleanor and Lou Gehrig ALS Center, Columbia University, New York, NY, USA. ns327@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS106236</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R38 CA231577</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2022 Jan;28(1):25-27</RefSource><PMID Version="1">35075291</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Mol Med. 2022 Apr;28(4):253-254</RefSource><PMID Version="1">35246398</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>P.J.-N. is employed by Ionis Pharmaceuticals, a for-profit company that develops ASO therapies. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35075293</ArticleId><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01615-z</ArticleId><ArticleId IdType="pii">10.1038/s41591-021-01615-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M, Brown RHJr. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb. Perspect. Med. 2018;8:a024125. doi: 10.1101/cshperspect.a024125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024125</ArticleId><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RHJr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, Al-Chalabi A. The genetic architecture of ALS. Neurobiol. Dis. 2021;147:105156. doi: 10.1016/j.nbd.2020.105156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105156</ArticleId><ArticleId IdType="pubmed">33130222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJJr, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Broustal O, et al. FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. J. Alzheimers Dis. 2010;22:765&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">21158017</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T, et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology. 2010;74:366&#x2013;371. doi: 10.1212/WNL.0b013e3181ccc732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ccc732</ArticleId><ArticleId IdType="pubmed">20124201</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Trends in understanding the pathological roles of TDP-43 and FUS proteins. Adv. Exp. Med. Biol. 2021;1281:243&#x2013;267. doi: 10.1007/978-3-030-51140-1_15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-51140-1_15</ArticleId><ArticleId IdType="pubmed">33433879</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 2014;10:337&#x2013;348. doi: 10.1038/nrneurol.2014.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.78</ArticleId><ArticleId IdType="pubmed">24840975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, et al. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat. Commun. 2016;7:10465. doi: 10.1038/ncomms10465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10465</ArticleId><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="pubmed">26842965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD. ALS genetics: gains, losses, and implications for future therapies. Neuron. 2020;108:822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>St George-Hyslop P, et al. The physiological and pathological biophysics of phase separation and gelation of RNA binding proteins in amyotrophic lateral sclerosis and fronto-temporal lobar degeneration. Brain Res. 2018;1693:11&#x2013;23. doi: 10.1016/j.brainres.2018.04.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.04.036</ArticleId><ArticleId IdType="pmc">PMC6018615</ArticleId><ArticleId IdType="pubmed">29723523</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Hum. Mutat. 2010;31:E1377&#x2013;E1389. doi: 10.1002/humu.21241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21241</ArticleId><ArticleId IdType="pmc">PMC2922682</ArticleId><ArticleId IdType="pubmed">20232451</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte A, et al. P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul. Disord. 2012;22:73&#x2013;75. doi: 10.1016/j.nmd.2011.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2011.08.003</ArticleId><ArticleId IdType="pubmed">21907581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalancette-Hebert M, Sharma A, Lyashchenko AK, Shneider NA. Gamma motor neurons survive and exacerbate alpha motor neuron degeneration in ALS. Proc. Natl Acad. Sci. USA. 2016;113:E8316&#x2013;E8325. doi: 10.1073/pnas.1605210113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1605210113</ArticleId><ArticleId IdType="pmc">PMC5187676</ArticleId><ArticleId IdType="pubmed">27930290</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D, et al. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J. Neurosci. 2000;20:2534&#x2013;2542. doi: 10.1523/JNEUROSCI.20-07-02534.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-07-02534.2000</ArticleId><ArticleId IdType="pmc">PMC6772256</ArticleId><ArticleId IdType="pubmed">10729333</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 2006;9:408&#x2013;419. doi: 10.1038/nn1653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1653</ArticleId><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Almer G, et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 2002;58:1277&#x2013;1279. doi: 10.1212/WNL.58.8.1277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.8.1277</ArticleId><ArticleId IdType="pubmed">11971099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992;140:691&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Shanware NP, Bowler MJ, Tibbetts RS. Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. J. Biol. Chem. 2010;285:34097&#x2013;34105. doi: 10.1074/jbc.M110.154831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.154831</ArticleId><ArticleId IdType="pmc">PMC2962508</ArticleId><ArticleId IdType="pubmed">20720006</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Jiang X, Chen G, Xu J. Interaction of amyotrophic lateral sclerosis/frontotemporal lobar degeneration-associated fused-in-sarcoma with proteins involved in metabolic and protein degradation pathways. Neurobiol. Aging. 2015;36:527&#x2013;535. doi: 10.1016/j.neurobiolaging.2014.07.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.044</ArticleId><ArticleId IdType="pubmed">25192599</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks GG, et al. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat. Genet. 2000;24:175&#x2013;179. doi: 10.1038/72842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/72842</ArticleId><ArticleId IdType="pubmed">10655065</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey J, et al. FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention. Nucleic Acids Res. 2020;48:6889&#x2013;6905. doi: 10.1093/nar/gkaa410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa410</ArticleId><ArticleId IdType="pmc">PMC7337901</ArticleId><ArticleId IdType="pubmed">32479602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M, et al. Proteomic analysis of FUS interacting proteins provides insights into FUS function and its role in ALS. Biochim. Biophys. Acta. 2016;1862:2004&#x2013;2014. doi: 10.1016/j.bbadis.2016.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.07.015</ArticleId><ArticleId IdType="pmc">PMC5055831</ArticleId><ArticleId IdType="pubmed">27460707</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, et al. Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism. eLife. 2018;7:e37754. doi: 10.7554/eLife.37754.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.37754</ArticleId><ArticleId IdType="pmc">PMC6103746</ArticleId><ArticleId IdType="pubmed">30003873</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi J, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab. 2011;13:195&#x2013;204. doi: 10.1016/j.cmet.2011.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2011.01.010</ArticleId><ArticleId IdType="pmc">PMC3033043</ArticleId><ArticleId IdType="pubmed">21284986</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler M, Stecker K, Bennett CF. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 1997;77:379&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354772</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, C. Tailored treatment for ALS poised to move ahead. Nat. Med.10.1038/d41591-019-00013-w (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">32467611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>A study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ION363 in amyotrophic lateral sclerosis participants with fused in sarcoma mutations (FUS-ALS). ClinicalTrials.govhttps://ClinicalTrials.gov/show/NCT04768972 (2021).</Citation></Reference><Reference><Citation>Teplova M, et al. Crystal structure and improved antisense properties of 2&#x2032;-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 1999;6:535&#x2013;539. doi: 10.1038/9304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/9304</ArticleId><ArticleId IdType="pubmed">10360355</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Gorman S, Dagenais NA, Qian M, Marchuk Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc. Natl Acad. Sci. USA. 1997;94:14602&#x2013;14607. doi: 10.1073/pnas.94.26.14602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.26.14602</ArticleId><ArticleId IdType="pmc">PMC25067</ArticleId><ArticleId IdType="pubmed">9405659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Wang C, Sun H, LeRoith D, Yakar S. High-efficient FLPo deleter mice in C57BL/6J background. PLoS ONE. 2009;4:e8054. doi: 10.1371/journal.pone.0008054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008054</ArticleId><ArticleId IdType="pmc">PMC2777316</ArticleId><ArticleId IdType="pubmed">19956655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiihashi G, et al. Mislocated FUS is sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice. Brain. 2016;139:2380&#x2013;2394. doi: 10.1093/brain/aww161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww161</ArticleId><ArticleId IdType="pubmed">27368346</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, et al. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. eLife. 2016;5:e17820. doi: 10.7554/eLife.17820.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.17820</ArticleId><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>